en
svPress releases
Regulatory press release 2023-05-04
Interim Report First Quarter 2023
Regulatory press release 2023-05-02
Notice of extraordinary general meeting in Xspray Pharma AB (publ)
Regulatory press release 2023-05-02
Xspray announces a rights issue of units of approximately SEK 300 million ahead of Dasynoc product launch
Press release 2023-04-26
Xspray Pharma receives expected partial decision in patent case regarding matter of law
Regulatory press release 2023-04-13
Notice of annual general meeting of Xspray Pharma AB (publ)
Regulatory press release 2023-03-29
Xspray Pharma publishes its Annual Report 2022
Press release 2023-03-13
Board member in Xspray Pharma acquires shares from the CEO
Regulatory press release 2023-02-23
Xspray Pharma Partners with EVERSANA for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)
Regulatory press release 2023-02-15
Interim Report Fourth Quarter 2022
Press release 2022-12-13